Klinikum Mutterhaus der Borromaeerinnen gGmbH
- Address
- lock Available on a paid plan
Digestive System Diseases
At Klinikum Mutterhaus der Borromaeerinnen gGmbH, the Internal Medicine department conducts studies on gastrointestinal cancers, aiming to test innovative therapies, refine diagnostic markers, and improve patient outcomes. Research focuses on conditions such as colon cancer, rectal cancer, gastric and esophageal adenocarcinoma, and hepatocellular carcinoma.
- Colon cancer stage II and III with adjuvant strategies
- Organ‑preserving approaches for locally advanced rectal cancer
- Neoadjuvant immunotherapy for esophageal adenocarcinoma
- Targeted treatment for gastric and gastro‑oesophageal junction adenocarcinoma
- Early‑stage hepatocellular carcinoma evaluated with combination therapy
The site participates in 36 clinical trials led by 20 investigators, contributing to the European research network from its Trier location.
Hemic and Lymphatic Diseases
The hematology‑oncology team investigates blood‑forming and lymphatic malignancies, seeking to introduce new targeted agents, immunotherapies, and transplant protocols. Key disease areas include acute leukemias, mantle‑cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma.
- Philadelphia‑positive acute lymphoblastic leukemia with novel kinase inhibitors
- Acute myeloid leukemia with adverse genetic risk profiles
- Mantle‑cell lymphoma incorporating BTK inhibition
- High‑risk chronic lymphocytic leukemia treated with acalabrutinib‑based combinations
- Multiple myeloma evaluating next‑generation proteasome inhibitors
Across the 36 trials, investigators aim to enhance survival while reducing treatment‑related toxicity for patients with these hematologic cancers.
Immune System Diseases
Research on immune‑mediated malignancies centers on Hodgkin lymphoma and related checkpoint‑inhibitor strategies. Studies assess the safety and efficacy of personalized immunotherapy regimens, antibody‑drug conjugates, and novel combination approaches to boost response rates.
- Early‑stage unfavorable classical Hodgkin lymphoma with PET‑guided checkpoint blockade
- Relapsed/refractory follicular lymphoma treated with epcoritamab‑based therapy
- Triple‑negative breast cancer receiving combined PD‑1 inhibition and chemotherapy
- Immune‑based adjuvant therapy for intermediate‑stage hepatocellular carcinoma
- PD‑1 blockade in esophageal adenocarcinoma as part of organ‑preserving protocols
The trials are integrated within European collaborative networks, emphasizing patient‑centred outcomes and reduced adverse effects.
Neoplasms
Broad oncology research at the site addresses solid tumors beyond the digestive tract, including breast, ovarian, and endometrial cancers. The objective is to evaluate new targeted molecules, hormone‑based combinations, and antibody‑drug conjugates to improve disease‑free survival and quality of life.
- Hormone‑receptor positive/HER2‑negative breast cancer with CDK4/6 inhibition
- HER2‑positive early breast cancer receiving trastuzumab‑deruxtecan
- High‑risk ovarian, fallopian tube, or peritoneal cancer with platinum‑based therapy
- pMMR endometrial carcinoma evaluated with sacituzumab‑based maintenance
- Metastatic colorectal cancer without liver metastases treated with Fruquintinib and PD‑1 inhibition
The 36 active trials, supported by 20 investigators, contribute to advancing cancer care across Europe from the Trier campus.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 5 therapeutic areas and 15 of 101 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 101 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 16 by active trials.
lock +15 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Mutterhaus der Borromaeerinnen gGmbH
lock Showing 1 of 43 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients with PIK3CA -Mutant, Hormone Receptor-Positive, HER2 -Negative Locally Advanced or Metastatic Breast Cancer | F. Hoffmann-La Roche AG | Phase III | Not Recruiting | Aug 2020 | — |
IMP list
lock Showing 1 of 101 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 7 | Unknown | 2019-12-04 | 2025-10-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.